Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity of the trivalent inactivated influenza vaccine in young children less than 4 years of age, with a focus on age and baseline antibodies.
Mugitani A, Ito K, Irie S, Eto T, Ishibashi M, Ohfuji S, Fukushima W, Maeda A, Hirota Y; Fukuoka Pediatricians Group for Vaccine Efficacy. Mugitani A, et al. Among authors: irie s. Clin Vaccine Immunol. 2014 Sep;21(9):1253-60. doi: 10.1128/CVI.00200-14. Epub 2014 Jul 2. Clin Vaccine Immunol. 2014. PMID: 24990904 Free PMC article.
Prior vaccinations improve immunogenicity of inactivated influenza vaccine in young children aged 6 months to 3 years: A cohort study.
Ito K, Mugitani A, Irie S, Ishibashi M, Takasaki Y, Shindo S, Yokoyama T, Yamashita Y, Shibao K, Koyanagi H, Fukushima W, Ohfuji S, Maeda A, Kase T, Hirota Y. Ito K, et al. Among authors: irie s. Medicine (Baltimore). 2018 Jul;97(29):e11551. doi: 10.1097/MD.0000000000011551. Medicine (Baltimore). 2018. PMID: 30024549 Free PMC article. Clinical Trial.
Comparison of immunogenicity between candidate influenza A(H3N2) virus vaccine strains in Japan: A randomized controlled trial using a monovalent vaccine of A/Saitama/103/2014 (CEXP-002) and A/Hong Kong/4801/2014 (X-263).
Kase T, Inoue M, Morikawa S, Kumashiro H, Hiroi S, Nakata K, Ito K, Ishibashi M, Tsuru T, Irie S, Maeda A, Ohfuji S, Fukushima W, Hirota Y. Kase T, et al. Among authors: irie s. Vaccine. 2020 Sep 29;38(42):6524-6532. doi: 10.1016/j.vaccine.2020.08.025. Epub 2020 Aug 29. Vaccine. 2020. PMID: 32873406 Free article. Clinical Trial.
SARS-CoV-2 Seroprevalence among Healthcare Workers in General Hospitals and Clinics in Japan.
Yoshihara T, Ito K, Zaitsu M, Chung E, Aoyagi I, Kaji Y, Tsuru T, Yonemura T, Yamaguchi K, Nakayama S, Tanaka Y, Yurino N, Koyanagi H, Matsuki S, Urae R, Irie S. Yoshihara T, et al. Among authors: irie s. Int J Environ Res Public Health. 2021 Apr 5;18(7):3786. doi: 10.3390/ijerph18073786. Int J Environ Res Public Health. 2021. PMID: 33916399 Free PMC article.
Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case-Control Study.
Hara M, Furue T, Fukuoka M, Iwanaga K, Matsuishi E, Miike T, Sakamoto Y, Mukai N, Kinugasa Y, Shigyo M, Sonoda N, Tanaka M, Arase Y, Tanaka Y, Nakashima H, Irie S, Hirota Y. Hara M, et al. Among authors: irie s. Vaccines (Basel). 2022 May 14;10(5):779. doi: 10.3390/vaccines10050779. Vaccines (Basel). 2022. PMID: 35632535 Free PMC article.
440 results